Moving beyond efforts to optimize mTOR or EGFR-targeted strategies for HNSCC, Qiu et al. [21] employed genome-wide CRISPR Cas9 screening to uncover vulnerabilities that enhance responsiveness to oncolytic virotherapy with oHSV-1. Here, MTOR is linked to head and neck squamous cell carcinoma.